Clinical trials: Fistulizing Crohn's Disease, active
Inflammatory Bowel Disease (IBD), Crohn Disease
Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study
This study aims to test a new treatment called hyperbaric oxygen therapy (HBOT) for a severe type of inflammatory bowel disease called perianal Crohn's disease (PCD).
- Trial name
- HYPNOTIC (NCT06109961)
- Testing
- Oxygen Gas for Inhalation, Standard of care
- Volunteers
- 54 people
- Sponsor
- University of British Columbia
Perianal Fistula Due to Crohn's Disease
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing…
- Trial name
- NCT06918808
- Testing
- DB-3Q
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Crohn Disease
Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease
This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
- Trial name
- NCT06739278
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Fistulizing Crohns Disease, Perianal Crohns Disease
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
- Trial name
- FUZION CD (NCT05347095)
- Testing
- Guselkumab
- Where
- 154 sites in United States, Australia and 21 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn Disease, Perianal Fistula
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Crohn's disease is an inflammatory bowel disease characterized by relapses and remissions, causing lesions throughout the digestive tract and accompanied by diarrhea, abdominal pain, and nutritional disorders.
- Conditions
- Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
- Trial name
- RIS-PERIANAL (NCT07872449)
- Testing
- Risankizumab
- Where
- 4 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Yuki Horio
Crohn Disease, Infliximab
TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab (RemsimaTM) intravenous therapy for patients with…
- Conditions
- Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease, Therapeutic Drug Monitoring
- Trial name
- NCT06051253
- Testing
- TDM-based infliximab intravenous therapy, Standard infliximab intravenous therapy
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Asan Medical Center
Crohn Disease (CD), Perianal Crohns Disease
Regenerative Endoscopy in Refractory Perianal Crohn's Disease
Perianal fistulizing Crohn's disease (pCD) represents a severe phenotype of Crohn's disease, affecting approximately 20-30% of patients and resulting in chronic drainage, recurrent sepsis, impaired continence, and reduced quality…
- Trial name
- REPAIR-pCD (NCT07652632)
- Testing
- Autologous Mechanical Tissue Stromal Vascular Fraction (tSVF) Injection
- Where
- 2 sites in India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn's Disease, Perianal Fistula
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
This Phase 4, single-arm, open-label study will evaluate the effectiveness and safety of mirikizumab combined with surgical curettage and closure in adults with active perianal fistulizing Crohn's disease.
- Trial name
- MIRICURE (NCT07782021)
- Testing
- Mirikizumab, Fistula Tract Curettage and Closure
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Icahn School of Medicine at Mount Sinai